No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing

Sandra Franco; Maria Casadellà; Marc Noguera-Julian; Bonaventura Clotet; Cristina Tural; Roger Paredes; Miguel Angel Martinez

doi:10.1016/j.jcv.2013.09.022

No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing

Sandra Franco, Maria Casadellà, Marc Noguera-Julian, Bonaventura Clotet, Cristina Tural, Roger Paredes, Miguel Angel Martinez

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

16 Cites (Scopus)

Resum

Background: The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors. Objective: We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients. Study design: NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples. Results: No S282T variant was detected in the 16 analyzed samples. Conclusion: This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds. © 2013 Elsevier B.V.

Idioma original	Anglès
Pàgines (de-a)	726-729
Revista	Journal of Clinical Virology
Volum	58
Número	4
DOIs	https://doi.org/10.1016/j.jcv.2013.09.022
Estat de la publicació	Publicada - 1 de des. 2013

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1016/j.jcv.2013.09.022

Altres arxius i enllaços

https://www.scopus.com/pages/publications/84888846936

Com citar-ho

@article{e8b6363c6aa3473f884bd959705f209f,

title = "No detection of the NS5B S282T mutation in treatment-na{\"i}ve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing",

abstract = "Background: The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors. Objective: We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients. Study design: NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples. Results: No S282T variant was detected in the 16 analyzed samples. Conclusion: This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds. {\textcopyright} 2013 Elsevier B.V.",

keywords = "Deep sequencing, HCV, NS5B, Resistance, S282T",

author = "Sandra Franco and Maria Casadell{\`a} and Marc Noguera-Julian and Bonaventura Clotet and Cristina Tural and Roger Paredes and Martinez, \{Miguel Angel\}",

year = "2013",

month = dec,

day = "1",

doi = "10.1016/j.jcv.2013.09.022",

language = "English",

volume = "58",

pages = "726--729",

journal = "Journal of Clinical Virology",

issn = "1386-6532",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing

AU - Franco, Sandra

AU - Casadellà, Maria

AU - Noguera-Julian, Marc

AU - Clotet, Bonaventura

AU - Tural, Cristina

AU - Paredes, Roger

AU - Martinez, Miguel Angel

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background: The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors. Objective: We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients. Study design: NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples. Results: No S282T variant was detected in the 16 analyzed samples. Conclusion: This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds. © 2013 Elsevier B.V.

AB - Background: The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors. Objective: We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients. Study design: NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples. Results: No S282T variant was detected in the 16 analyzed samples. Conclusion: This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds. © 2013 Elsevier B.V.

KW - Deep sequencing

KW - HCV

KW - NS5B

KW - Resistance

KW - S282T

UR - https://www.scopus.com/pages/publications/84888846936

U2 - 10.1016/j.jcv.2013.09.022

DO - 10.1016/j.jcv.2013.09.022

M3 - Article

SN - 1386-6532

VL - 58

SP - 726

EP - 729

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

IS - 4

ER -

No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho